1880-800KV-定.png

2023年欧洲肿瘤内科学会（ESMO）年会将于10月20日-24日在西班牙马德里召开。ESMO大会涵盖基础研究、转化研究以及最新临床研究进展，将为临床实践、多学科讨论等提供广阔、卓越的学术平台。医脉通整理了壁报部分晚期非小细胞肺癌（NSCLC）领域中国专家入选的研究成果，以飨读者。

摘要号：1325P

英文标题：Sunvozertinib as First-line Treatment in NSCLC Patients with EGFR Exon20 Insertion Mutations Sunvozertinib

中文标题：舒沃替尼一线治疗EGFR外显子20插入突变NSCLC患者

讲者：James Chih-Hsin Yang 台湾

摘要号：1330P

英文标题：Updated results of the efficacy and safety of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer (NSCLC) who failed prior EGFR-TKI(s)

中文标题：KN046（一种双特异性抗PD-L1/CTLA-4）对先前EGFR-TKI失败的转移性NSCLC的有效性和安全性的最新结果

讲者：周彩存同济大学附属上海市肺科医院

摘要号：1332P

英文标题：Efficacy and safety of gefitinib plus bevacizumab versus gefitinib monotherapy in patients with EGFR L858R mutant non-small cell Lung cancer (NSCLC): A randomized, open-controlled, single-center trial

中文标题：吉非替尼联合贝伐单抗对比吉非替尼单药治疗EGFR L858R突变NSCLC患者的疗效和安全性：一项随机、开放对照、单中心试验

讲者：Jialei Wang 上海

摘要号：1337P

英文标题：Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation–positive NSCLC: an interim analysis of the ARIA study

中文标题：达可替尼作为一线治疗亚洲晚期EGFR突变阳性NSCLC患者的实际应用和疗效：ARIA研究的中期分析

讲者：邬麟湖南省肿瘤医院

摘要号：1340P

英文标题：Propensity score matching analysis for osimertinib versus comparator first-generation EGFR tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non–small cell lung cancer：A Chinese, Multicenter, Real-World Cohort Study.

中文标题：奥希替尼对比第一代EGFR-TKI作为晚期EGFR突变NSCLC一线治疗的倾向性评分匹配分析：一项中国、多中心、真实世界的队列研究

讲者：Dongming Zhang 北京

摘要号：1341P

英文标题：Real World Molecular Testing, Treatment Patterns and Clinical outcomes in Chinese Advanced NSCLC patients, Who Have Progressed on First-line EGFR-TKI Therapy (PISCES)

中文标题：在一线EGFR-TKI治疗（PISCES）中取得进展的中国晚期NSCLC患者的真实世界分子检测、治疗模式和临床结果

讲者：Panwen Tian 成都

摘要号：1342P

英文标题：Effect of the timing of intervention in craniocerebral radiotherapy on prognosis of patients with EGFR-mutant lung adenocarcinoma with brain metastasis

中文标题：颅脑放疗干预时机对EGFR突变肺腺癌脑转移患者预后的影响

讲者：Guangchuan Deng 济南

摘要号：1346P

英文标题：Efficacy and Safety of High Dose Furmonertinib Combined with Intrathecal Injection in EGFR-mutated Advanced NSCLC Patients with LM Progressed on Osimertinib

中文标题：高剂量伏美替尼联合鞘内注射治疗奥希替尼治疗进展的伴脑转移的EGFR突变晚期NSCLC患者的疗效和安全性

讲者：Xiaoyan Li 北京

摘要号：1349P

英文标题：Continuing Osimertinib in combination with Chemotherapy after Osimertinib Failure reduces CNS progression in patients with EGFR-mutated NSCLC and CNS metastases

中文标题：奥希替尼失败后继续奥希替尼联合化疗可减少EGFR突变NSCLC和CNS转移患者的CNS进展

讲者：Molly Li 香港

摘要号：1351P

英文标题：Efficacy of early stereotactic body radiotherapy to the primary lung lesion in patients with NSCLC harboring sensitive EGFR mutations treated with first-line EGFR-TKIs

中文标题：早期立体定向放射治疗对接受一线EGFR-TKIs治疗的EGFR突变NSCLC原发性肺部病变的疗效

讲者：Dan Tao 重庆

摘要号：1352P

英文标题：Plasma metabolic signatures uncover therapeutic response and prognosis of third-generation EGFR-TKI treatment in patients with NSCLC

中文标题：血浆代谢特征揭示第三代EGFR-TKI治疗NSCLC患者的疗效和预后

讲者：Ruyun Gao 北京

摘要号：1354P

英文标题：Beyond the Common Mutation: Examining Chemotherapy Success in Uncommon EGFR Mutations

中文标题：常见突变之外：检测罕见EGFR突变的化疗成功率

讲者：Chien-Chung Lin 台湾

摘要号：1357P

英文标题：Bevacizumab improved prognosis for advanced EGFR mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy.

中文标题：贝伐珠单抗可改善接受脑放射治疗的晚期EGFR突变型肺腺癌脑转移患者的预后

讲者：YuanLiang Zhou 济南

摘要号：1364P

英文标题：ctDNA analysis of SAF-189s efficacy in ALK+ advanced non-small cell lung cancer (NSCLC)

中文标题：SAF-189s治疗ALK+晚期NSCLC疗效的ctDNA分析

讲者：杨衿记广东省人民医院

摘要号：1370P

英文标题：Efficacy and safety of ensartinib in ALK-positive non-small cell lung cancer patients with brain metastases: A multicenter, open-label, single-arm, phase 2 study

中文标题：恩沙替尼治疗脑转移的ALK阳性NSCLC的疗效和安全性：一项多中心、开放标签、单臂、2期研究

讲者：Jianhua Chang 深圳

摘要号：1378P

英文标题：Efficacy and Safety of Tunlametinib (HL-085) combined with Vemurafenib in Patients with Advanced BRAF V600-mutated Solid Tumors: A Multicenter, Phase I Study

中文标题：Tunlametinib (HL-085) 联合维莫非尼治疗晚期 BRAF V600 突变实体瘤患者的疗效和安全性：一项多中心 I 期研究

讲者：石远凯中国医学科学院肿瘤医院

摘要号：1379P

英文标题：Vebreltinib in Patients (Pts) with Advanced NSCLC Harboring c-MET exon 14 skipping mutation from a Phase II Study

中文标题：Vebreltinib 用于治疗携带 c-MET 外显子 14 跳跃突变的晚期 NSCLC的II 期研究

讲者：杨衿记广东省人民医院

摘要号：1387P

英文标题：Efficacy of First-line Treatment Options in Advanced HER2-altered Non-small Cell Lung Cancer: A Multi-center Retrospective Study

中文标题：一线治疗方案对晚期HER2突变NSCLC的疗效：一项多中心回顾性研究

讲者：Haifeng Sun 郑州

摘要号：1393P

英文标题：Characteristics of MET gene and its relationship with TMB/MMR genes in Chinese NSCLC population

中文标题：中国NSCLC人群MET基因特征及其与TMB/MMR基因的关系

讲者：Hong Yi Zhang 福州

摘要号：1409P

英文标题：DEnosumab in Combination with PD-1 Checkpoint Blockade for MAINtenance Therapy of KRAS-Mutant Advanced NSCLC after First-Line Immunotherapy - A Prospective, Single-Arm, Phase II Trial (DEMAIN)

中文标题：地舒单抗联合PD-1抑制剂用于一线免疫治疗后KRAS突变型晚期NSCLC的维持治疗——一项前瞻性单臂II期试验（DEMAIN）

讲者：Hong-Shuai Li 北京

摘要号：1413P

英文标题：Patient-reported outcomes (PROs) from a phase 2 trial of telisotuzumab vedotin (Teliso-V) in c-Met–overexpressing, EGFR wild type, non-squamous non-small cell lung cancer (c-Met OE, EGFR WT, NSq NSCLC)

中文标题：telisotuzumab vedotin（Teliso-V）治疗c-Met过表达、EGFR野生型、非鳞状NSCLC（c-Met OE、EGFR WT、NSq NSCLC）的2期试验的患者报告结果（PROs）

讲者：陆舜上海交通大学附属胸科医院

摘要号：1414P

英文标题：Impact of Co-mutations on the Prognosis of Targeted Therapy in EGFR-Mutant Advanced NSCLC: a Result of Real-World Study

中文标题：共突变对EGFR突变型晚期NSCLC靶向治疗预后的影响：一项真实世界研究结果

讲者：Sisi Pan 晋中

摘要号：1421P

英文标题：AI-Powered Intracranial Tumor Response Predicts Systemic Progression with High Concordance in Endpoint Evaluation in the Phase III CROWN Study

中文标题：人工智能驱动的颅内肿瘤反应可预测系统进展，并且在 III 期 CROWN 研究中终点评估具有高度一致性

讲者：Shao-Lun Lu 台湾

摘要号：1424P

英文标题：Outcome of thromboembolic events and its influence on survival time of advanced NSCLC patients receiving antiangiogenic therapy

中文标题：接受抗血管生成治疗的晚期NSCLC患者血栓栓塞事件的结局及其对生存时间的影响

讲者：Wei-Fan Ou 台湾

摘要号：1427P

英文标题：Exploration of the value of leptomeningeal biopsy in diagnosing and treating non-small cell lung cancer with leptomeningeal metastasis

中文标题：探讨脑膜活检在诊断和治疗伴有脑膜转移的非小细胞肺癌中的价值

讲者：Lin B. Cai 广州

摘要号：1436P

英文标题：Prospective Study Utilizing ctDNA genome-wide copy number variations for Longitudinal Monitoring of Patients with Advanced Non-Small Cell Lung Cancer

中文标题：应用ctDNA全基因组拷贝数变异对晚期NSCLC进行纵向监测的前瞻性研究

讲者：Pengkai Han 重庆

摘要号：1439P

英文标题：Brain radiotherapy combined with camrelizumab and platinum-based chemotherapy as first-line treatment for advanced NSCLC with brain metastases: a multicenter, open-label, single-arm, phase 2 study

中文标题：脑放射治疗联合卡瑞利珠单抗和铂类化疗作为晚期NSCLC脑转移的一线治疗：一项多中心、开放标签、单臂、2期研究

讲者：范云浙江省肿瘤医院

摘要号：1444P

英文标题：Sintilimab with two cycles nab-paclitaxel / platinum as first line therapy for advanced squamous non–small-cell lung cancer: the final analysis and biomarker results

中文标题：信迪利单抗联合两周期白蛋白结合型紫杉醇/铂作为晚期鳞状NSCLC的一线治疗：最终分析和生物标志物结果

讲者：王慧娟河南省肿瘤医院

·

摘要号：1449P

英文标题：The preliminary data from a single-arm, open-label, multicenter phase 2 clinical trial ：KN046 combined with axitinib as first-line (1L) treatment for NSCLC.

中文标题：来自单臂、开放标签、多中心2期临床试验的初步数据：KN046联合阿昔替尼作为NSCLC的一线治疗

讲者：Yuanyuan Zhao 青岛

摘要号：1458P

英文标题：Pucotenlimab (HX008) - Humanized Anti-PD-1 Monoclonal Antibody Plus Pemetrexed and Platinum as First-line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer (nsqNSCLC): a Single-Arm Multicenter Phase II Study

中文标题：Pucotenlimab（HX08）-人源化抗PD-1单克隆抗体联合培美曲塞和铂作为晚期nsqNSCLC一线治疗：一项单臂多中心II期研究

讲者：周彩存同济大学附属上海市肺科医院

摘要号：1459P

英文标题：Preliminary efficacy and safety of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer who previously treated with immune checkpoint inhibitor(s)

中文标题：KN046（一种双特异性抗PD-L1/CTLA-4）对转移性NSCLC的初步疗效和安全性

讲者：周彩存同济大学附属上海市肺科医院

摘要号：1463P

英文标题：IL-6 triggers chemoimmunotherapy resistance by creating immunosuppressive tumor microenvironment in non-small cell lung cancer

中文标题：IL-6通过在NSCLC中产生免疫抑制肿瘤微环境来触发化学免疫疗法耐药性

讲者：Yaning Yang 北京

摘要号：1466P

英文标题：Gut microbiota mediates the protective effects of postbiotics attenuating the immune-related adverse events in Non-Small-Cell Lung Cancer patients: a randomized, controlled trial in Chongqing, China

中文标题：肠道微生物群介导抗生素减轻非小细胞肺癌癌症患者免疫相关不良事件的保护作用：中国重庆的一项随机对照试验

讲者：Huiqing Yu 重庆

摘要号：1467P

英文标题：Combination Therapy of Envafolimab and Suvemcitug with chemotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC): Results from a Phase II Clinical Trial

中文标题：Envafolimab和Suvemcitug联合化疗治疗NSCLC：II期临床试验结果

讲者：Chunjiao Wu 长春

摘要号：1487P

英文标题：Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer：Updated results

中文标题：安罗替尼联合PD-1/PD-L1抑制剂作为晚期NSCLC一线或二线治疗的真实疗效和安全性：最新结果

讲者：王启鸣河南省肿瘤医院

摘要号：1489P

英文标题：To investigate the differences in efficacy between immunotherapy and combined immunotherapy in elderly patients with non-small cell lung cancer

中文标题：研究免疫疗法和联合免疫疗法在老年NSCLC中的疗效差异

讲者：Ye Y. Mao 北京

摘要号：1494P

英文标题：Fruquintinib combined with sintilimab and chemotherapy as the first-line treatment in advanced naive EGFR- and ALK-negative non-squamous non-small cell lung cancer(nsq-NSCLC): Updated results of a phase Ⅱ trial

中文标题：呋喹替尼联合信迪利单抗和化疗一线治疗晚期EGFR和ALK阴性nsq-NSCLC：Ⅱ期试验的最新结果

讲者：束永前江苏省人民医院

摘要号：1497P

英文标题：Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in Untreated advanced Non-Small-Cell lung cancer

中文标题：肠道微生物组与未治疗的晚期NSCLC抗PD-1免疫疗法的临床反应相关

讲者：Yawen Bin 武汉

摘要号：1504TiP

英文标题：HARMONi: Randomized, Double-blind, Multi-center, Phase 3 Clinical Study of Ivonescimab or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Progression Following EGFR-TKI Treatment

中文标题：HARMONi：Ivonescimab或安慰剂联合培美曲塞和卡铂治疗EGFR-TKI进展的局部晚期或转移性非鳞状NSCLC的随机、双盲、多中心、3期临床研究

讲者：方文峰中山大学肿瘤防治中心